m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01585)
Name
Nabumetone
Synonyms
NNB-001; NNB-004; NNB-005; Nabumetone (oral); Nabumetone (oral), Nobex; 6-MNA (oral), Nobex
    Click to Show/Hide
Status
Approved
Structure
Formula
C15H16O2
InChI
1S/C15H16O2/c1-11(16)3-4-12-5-6-14-10-15(17-2)8-7-13(14)9-12/h5-10H,3-4H2,1-2H3
InChIKey
BLXXJMDCKKHMKV-UHFFFAOYSA-N
PubChem CID
4409
TTD Drug ID
D05CKR
INTEDE Drug ID
DR1122
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aldo-keto reductase 1C1 (AKR1C1)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Nabumetone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Nabumetone through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). [1], [2]
Prostaglandin G/H synthase 2 (COX-2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Nabumetone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nabumetone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). [3], [4]
References
Ref 1 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 2 Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35. doi: 10.1007/s13318-014-0190-0.
Ref 3 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.
Ref 4 Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7. doi: 10.1016/s0049-0172(97)80049-2.